Your browser doesn't support javascript.
loading
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.
Pfirrmann, Markus; Clark, Richard E; Prejzner, Witold; Lauseker, Michael; Baccarani, Michele; Saussele, Susanne; Guilhot, François; Heibl, Sonja; Hehlmann, Rüdiger; Faber, Edgar; Turkina, Anna; Ossenkoppele, Gert; Höglund, Martin; Zaritskey, Andrey; Griskevicius, Laimonas; Olsson-Strömberg, Ulla; Everaus, Hele; Koskenvesa, Perttu; Labar, Boris; Sacha, Tomasz; Zackova, Daniela; Cervantes, Francisco; Colita, Adriana; Zupan, Irena; Bogdanovic, Andrija; Castagnetti, Fausto; Guilhot, Joëlle; Hasford, Joerg; Hochhaus, Andreas; Hoffmann, Verena S.
Afiliación
  • Pfirrmann M; Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie - IBE, Ludwig-Maximilians Universität, Munich, Germany. pfi@ibe.med.uni-muenchen.de.
  • Clark RE; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
  • Prejzner W; Medical University of Gdansk, Gdansk, Poland.
  • Lauseker M; Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie - IBE, Ludwig-Maximilians Universität, Munich, Germany.
  • Baccarani M; Clinical Department of Hematology and Oncology L. and A. Seragnoli, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
  • Saussele S; III. Medizinische Klinik, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany.
  • Guilhot F; Clinical Investigation Centre, INSERM CIC 1402, CHU Poitiers, Poitiers, France.
  • Heibl S; Abteilung für Innere Medizin IV, Klinikum Wels-Grieskirchen, Wels, Austria.
  • Hehlmann R; III. Medizinische Klinik, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany.
  • Faber E; ELN Foundation, Weinheim, Germany.
  • Turkina A; Department of Hemato-Oncology, Faculty Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
  • Ossenkoppele G; National Research Center for Hematology, Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation.
  • Höglund M; Department of Hematology, VU University Medical Center, Amsterdam, Netherlands.
  • Zaritskey A; Institution of Medical Sciences, University of Uppsala, Uppsala, Sweden.
  • Griskevicius L; Almazov Medical Reseach Centre, Institute of Oncology and Hematology, St Petersburg, Russian Federation.
  • Olsson-Strömberg U; Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania.
  • Everaus H; Department of Medical Sciences, University of Uppsala and Section of Hematology, Uppsala University Hospital, Uppsala, Sweden.
  • Koskenvesa P; Tartu University Hospital, Tartu, Estonia.
  • Labar B; Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Sacha T; School of Medicine, University of Zagreb, Zagreb, Croatia.
  • Zackova D; Department of Hematology, Jagiellonian Unversity Medical College, Kraków, Poland.
  • Cervantes F; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
  • Colita A; Hematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain.
  • Zupan I; Romanian Academy of Medical Sciences and Medical University, Bucharest, Romania.
  • Bogdanovic A; Department of Hematology, University Medical Centre, Ljubljana, Slovenia.
  • Castagnetti F; Clinic of Hematology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Guilhot J; Clinical Department of Hematology and Oncology L. and A. Seragnoli, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
  • Hasford J; Clinical Investigation Centre, INSERM CIC 1402, CHU Poitiers, Poitiers, France.
  • Hochhaus A; Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie - IBE, Ludwig-Maximilians Universität, Munich, Germany.
  • Hoffmann VS; Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
Leukemia ; 34(8): 2138-2149, 2020 08.
Article en En | MEDLINE | ID: mdl-32601376
ABSTRACT
Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our aim was to compare the prognostic performance of the scores and to arrive at an evidence-based score recommendation. In 2949 patients not involved in any score development, higher hazard ratios and concordance indices in any comparison demonstrated the best discrimination of long-term survival with the ELTS score. In a second step, of 5154 patients analyzed to investigate risk group classification differences, 23% (n = 1197) were allocated to high-risk by the Sokal score. Of the 1197 Sokal high-risk patients, 56% were non-high-risk according to the ELTS score and had a significantly more favorable long-term survival prognosis than the 526 high-risk patients according to both scores. The Sokal score identified too many patients as high-risk and relatively few (40%) as low-risk (versus 60% with the ELTS score). Inappropriate risk classification jeopardizes optimal treatment selection. The ELTS score outperformed the Sokal score, the Euro, and the EUTOS score regarding risk group discrimination. The recent recommendation of the European LeukemiaNet for preferred use of the ELTS score was supported with significant statistical evidence.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva Tipo de estudio: Guideline / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva Tipo de estudio: Guideline / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Alemania
...